Sham Mailankody MD

Oncology•New York, NY

Physician

Request appointment

530 East 74th StreetNew York, NY 10021
Book by Phone+1(567) 483-1676

Overview of Dr. Mailankody

Dr. Sham Mailankody is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Kansas City University of Medicine and Biosciences College of Osteopathic Medicine and has been in practice 19 years. He is one of 537 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 100 publications and over 500 citings.

Education & Training

National Institutes of Health Clinical CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
MedStar Health Georgetown University/Washington Hospital CenterResidency, Internal Medicine, 2009 - 2012
K S Hegde Medical AcademyMBBS, 2001 - 2007
Kansas City University of Medicine and Biosciences College of Osteopathic MedicineClass of 2007

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

FL State Medical License 2022 - Present
NJ State Medical License 2022 - 2027
NY State Medical License 2015 - 2026
DC State Medical License 2009 - 2012
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2017
CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2017

Clinical Trials

Ixazomib (MLN9708) and Dexamethasone in High Risk Smoldering Multiple Myeloma: A Clinical and Correlative Pilot Study
COMPLETED
PHASE1
BCMA Targeted CAR T Cells With or Without Lenalidomide for the Treatment of Multiple Myeloma Start of enrollment: 2017 Feb 27
COMPLETED
PHASE1
Short Course Daratumumab in Patients With Multiple Myeloma Start of enrollment: 2018 May 03
COMPLETED
PHASE2

Publications & Presentations

PubMed

Chromatin-informed cell-free DNA approach for detection of clinically measurable disease in multiple myeloma.
Palak Bajaj, Dor David Abelman, Ping Luo, Michele Ceccarelli, Jonathan H Schatz
Blood Advances. 2026-10-06
More options, more questions in the management of early relapsed and/or refractory multiple myeloma.
Carlyn Rose Tan, Sham Mailankody
Nature Reviews. Clinical Oncology. 2026-10-01
1 citations
Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.
Vasiliki Kostiou, Vijayalakshmi Chelliah, Piet H van der Graaf, Andrzej M Kierzek, Tasmin Farzana
Clinical Pharmacology and Therapeutics. 2026-10-01